Integrated bioinformatics analysis and clinical validation identifies TNFSF14 and CD40 as novel biomarkers for chronic kidney disease progression and tubulointerstitial injury
International Urology and Nephrology · 2026
DOI: 10.1007/s11255-026-05138-9 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Xiameng Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Affiliated Hospital of Nantong University, Jiangsu, 226001, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, CD40 Antigens, Tumor Necrosis Factor Ligand Superfamily Member 14. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Project of Nantong City.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a global public health burden characterized by irreversible renal function loss and progressive fibrosis. Non-invasive biomarkers reflecting intra-renal inflammation and early tubulointerstitial injury remain an unmet clinical need. We combined bioinformatics analysis with clinical validation to characterize two immune-related genes, TNFSF14 and CD40, in CKD progression.
Methods
Two independent CKD transcriptomic datasets (GSE66494, n = 61; GSE97709, n = 48) were retrieved from the GEO database. Differentially Expressed Genes (DEGs) were screened with FDR adjustment. Clinical validation was performed in 140 CKD patients (KDIGO Stages I–V) and 60 healthy controls. TNFSF14 and CD40 levels were quantified in serum/urine via ELISA, with intra-renal expression assessed via immunofluorescence in 80 biopsy specimens. Multivariable regression was used to evaluate independent predictive value.
Results
TNFSF14 and CD40 were identified as core hub genes enriched in the TNF signaling pathway. Both markers were significantly elevated in serum/urine of CKD patients (Adjusted P < 0.05), with upregulation localized to renal tubular epithelial cells. Urinary levels increased in a CKD stage-dependent manner, positively correlating with serum creatinine/BUN and inversely with eGFR. Urinary TNFSF14 and CD40 were independent predictors of advanced CKD, with a combined diagnostic model achieving an AUC of 0.892 (95% CI: 0.851–0.933).
Conclusions
TNFSF14 and CD40 are robust molecular signatures of tubulointerstitial injury, and their urinary levels serve as non-invasive biomarkers for CKD detection and risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Affiliated Hospital of Nantong University, Jiangsu, 226001, China.
- Department of Pediatric Surgery, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
- Department of Nephrology, Affiliated Hospital of Nantong University, Jiangsu, 226001, China. chenxl8448@sina.com.
Förderung
- Science and Technology Project of Nantong City
Zitieren
APA
Gu, X., Lu, Y., Sha, H., Zhang, H., Chen, H., Qiu, M., & Chen, X. (2026). Integrated bioinformatics analysis and clinical validation identifies TNFSF14 and CD40 as novel biomarkers for chronic kidney disease progression and tubulointerstitial injury. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05138-9
Vancouver
Gu X, Lu Y, Sha H, Zhang H, Chen H, Qiu M, et al. Integrated bioinformatics analysis and clinical validation identifies TNFSF14 and CD40 as novel biomarkers for chronic kidney disease progression and tubulointerstitial injury. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05138-9
BibTeX
@article{Gu2026,
author = {Gu, Xiameng and Lu, Yuqing and Sha, Haonan and Zhang, Hanlu and Chen, Hongxin and Qiu, Mengyue and Chen, Xiaolan},
title = {Integrated bioinformatics analysis and clinical validation identifies TNFSF14 and CD40 as novel biomarkers for chronic kidney disease progression and tubulointerstitial injury},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05138-9}
}
EUVIMED